Cargando…
Presence of risk factors associated with colectomy among patients with ulcerative colitis: a post hoc analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical program
BACKGROUND: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). OBJECTIVE: To assess colectomy incidence rates (IRs) and baseline characteristics for the presence of identified colectomy risk factors among patients in the tofacitinib OCTAVE UC c...
Autores principales: | Rubin, David T., Salese, Leonardo, Cohen, Mitchell, Kotze, Paulo G., Woolcott, John C., Su, Chinyu, Mundayat, Rajiv, Paulissen, Jerome, Torres, Joana, Long, Millie D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408314/ https://www.ncbi.nlm.nih.gov/pubmed/37560161 http://dx.doi.org/10.1177/17562848231189122 |
Ejemplares similares
-
Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program
por: Hudesman, David P., et al.
Publicado: (2022) -
The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme
por: Farraye, Francis A., et al.
Publicado: (2021) -
Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials
por: Feagan, Brian G., et al.
Publicado: (2021) -
Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open
por: Panaccione, Remo, et al.
Publicado: (2022) -
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
por: Winthrop, Kevin L, et al.
Publicado: (2020)